Identifying Acute STEMI in the Presence of Paced Rhythm
EMS responds to a local coffee shop for a 77-year-old male who has reportedly fainted. While en route the call is upgraded to an unconscious patient and an engine company is dispatched for backup.
On arrival the patient is conscious but lethargic. He appears acutely ill. The skin is pale and diaphoretic. His past medical history includes hypertension, dyslipidemia, myocardial infarction, a coronary artery bypass graft and heart failure. His current medications are aspirin, metoprolol, atorvastatin, lisinopril and furosemide.
Upon further questioning he admits to chest discomfort. His OPQRST assessment is as follows:
≫ On...
Source: JEMS Patient Care - January 18, 2016 Category: Emergency Medicine Authors: Tom Bouthillet, NREMT-P Tags: Case of the Month Special Topics Cardiac & Resuscitation Patient Care Source Type: news
Identifying Acute STEMI in the Presence of Paced Rhythm
EMS responds to a local coffee shop for a 77-year-old male who has reportedly fainted. While en route the call is upgraded to an unconscious patient and an engine company is dispatched for backup.
On arrival the patient is conscious but lethargic. He appears acutely ill. The skin is pale and diaphoretic. His past medical history includes hypertension, dyslipidemia, myocardial infarction, a coronary artery bypass graft and heart failure. His current medications are aspirin, metoprolol, atorvastatin, lisinopril and furosemide.
Upon further questioning he admits to chest discomfort. His OPQRST assessment is as follows:
≫ On...
Source: JEMS Special Topics - January 18, 2016 Category: Emergency Medicine Authors: Tom Bouthillet, NREMT-P Tags: Case of the Month Special Topics Cardiac & Resuscitation Patient Care Source Type: news
The Biggest Medical Stories You May Have Missed In 2015
SPECIAL FROM Next Avenue By Craig Bowron As we head into the New Year, let’s take a look back and see what lessons we should have learned from medical science in 2015. The New England Journal of Medicine’s publication Journal Watch provides physicians and other health care providers with expert analysis of the most recent medical research. Below is a brief synopsis of what the Journal Watch editors felt were the most important stories in general medicine for the year 2015. While you likely heard about a couple, others probably escaped your radar. Getting Aggressive with Strokes We’re familiar with the...
Source: Science - The Huffington Post - January 15, 2016 Category: Science Source Type: news
Brent Saunders Softens His View On Research With Jim Cramer On 'Mad Money'
Drug discovery is a key component of R&D and Pfizer has a long history of discovering major new medicines, including drugs like Zoloft, Zithromax, Lipitor and, yes, Viagra. However, Saunders has made his reputation on repudiating the need for such investments. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 1, 2015 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent.
Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies.
Such a split would dramatically boost the compan...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news
Heart Disease and Diabetes Trials Anticipated at Kidney WeekHeart Disease and Diabetes Trials Anticipated at Kidney Week
New data will be presented on empagliflozin in patients with diabetes, and results from trials of atorvastatin and kidney injury after cardiac surgery will be released. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news
Impact of Dual Lipid-Lowering on Coronary PlaqueImpact of Dual Lipid-Lowering on Coronary Plaque
Find out how ezetimibe and atorvastatin combined impact coronary atherosclerosis in patients undergoing PCI. Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dr Reddy's recalls over 55K bottles of hypertension drug in US
Dr Reddy's Laboratories is recalling over 55,000 bottles of Amlodipine besylate and Atorvastatin calcium tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2015 Category: Pharmaceuticals Source Type: news
FTC clears Pfizer’s $15B Hospira buy
Pfizer (NYSE:PFE) said Monday it won approval from the Federal Trade Commission for its $15 billion acquisition of Hospira (NYSE:HSP).
The clearance came with a caveat –Pfizer must divest itself of its Acetylcysteine, Clindamycin, Voriconazole and Melphalan sterile injectable assets, according to the company.
The news from the FTC came August 21, according to an SEC filing from Hospira, and leaves the company with only 1 post-clearance waiting period in a single foreign jurisdiction, though the region was not specified.
Pfizer also announced that Brazil has given the merger the thumbs up.
“We are pleased to have...
Source: Mass Device - August 27, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Hospira Inc. Pfizer Inc. Source Type: news
Pfizer wins Canadian approval for $15B Hospira buy
Pfizer (NYSE:PFE) said it won approval from the Canadian Competition Bureau for its $15 billion acquisition of Hospira (NYSE:HSP).
As part of the agreement, the healthcare and pharmaceutical giant said it committed to divesting certain assets of the company in Canada, according to a press release.
“We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira. We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015,...
Source: Mass Device - August 14, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Hospira Inc. Pfizer Inc. Source Type: news
Pfizer Pulls The Plug On OTC Lipitor And It's The Patients' Fault
However, my guess is that payers will be disappointed by these results as they do not usually cover OTC medications and, despite the fact most statins are now generic, these drugs still impact their bottom-line. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2015 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
